First Trust Advisors LP Raises Stake in CryoLife Inc. (CRY)
First Trust Advisors LP boosted its stake in CryoLife Inc. (NYSE:CRY) by 40.7% during the second quarter, Holdings Channel reports. The institutional investor owned 40,819 shares of the company’s stock after buying an additional 11,803 shares during the period. First Trust Advisors LP owned about 0.12% of CryoLife worth $482,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently modified their holdings of CRY. EAM Investors LLC purchased a new position in shares of CryoLife during the second quarter valued at about $877,000. California Public Employees Retirement System boosted its position in shares of CryoLife by 28.4% in the second quarter. California Public Employees Retirement System now owns 116,800 shares of the company’s stock valued at $1,379,000 after buying an additional 25,800 shares in the last quarter. Emerald Acquisition Ltd. purchased a new position in shares of CryoLife during the second quarter valued at about $657,000. Swiss National Bank purchased a new position in shares of CryoLife during the second quarter valued at about $471,000. Finally, California State Teachers Retirement System boosted its position in shares of CryoLife by 22.3% in the second quarter. California State Teachers Retirement System now owns 66,083 shares of the company’s stock valued at $780,000 after buying an additional 12,045 shares in the last quarter. 58.13% of the stock is owned by hedge funds and other institutional investors.
CryoLife Inc. (NYSE:CRY) traded up 1.30% during trading on Wednesday, reaching $17.10. The company’s stock had a trading volume of 83,140 shares. CryoLife Inc. has a 52 week low of $8.94 and a 52 week high of $18.64. The firm has a market capitalization of $583.28 million, a P/E ratio of 54.81 and a beta of 1.05. The firm has a 50-day moving average price of $17.12 and a 200-day moving average price of $13.58.
CryoLife (NYSE:CRY) last issued its quarterly earnings data on Monday, July 25th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.11. CryoLife had a return on equity of 8.15% and a net margin of 5.80%. The business earned $47.10 million during the quarter, compared to analyst estimates of $35.50 million. During the same period in the prior year, the company posted $0.03 EPS. The business’s revenue for the quarter was up 32.6% compared to the same quarter last year. On average, equities analysts anticipate that CryoLife Inc. will post $0.34 EPS for the current fiscal year.
Several brokerages recently issued reports on CRY. Zacks Investment Research cut CryoLife from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Piper Jaffray Cos. reissued an “overweight” rating and set a $16.00 price target on shares of CryoLife in a research report on Wednesday, July 27th. Canaccord Genuity reissued a “buy” rating on shares of CryoLife in a research report on Tuesday, July 26th. Finally, Lake Street Capital initiated coverage on CryoLife in a research report on Wednesday, June 15th. They set a “buy” rating and a $15.00 price target for the company. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. CryoLife has an average rating of “Buy” and an average price target of $15.00.
In related news, Director C Elkins Ronald sold 2,000 shares of the stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $14.00, for a total value of $28,000.00. Following the completion of the transaction, the director now directly owns 103,586 shares of the company’s stock, valued at approximately $1,450,204. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 6.08% of the stock is owned by corporate insiders.
CryoLife Company Profile
CryoLife, Inc (CryoLife) is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment sells BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, Hemodialysis Reliable Outflow (HeRO) Graft, and ProCol Vascular Bioprosthesis (ProCol).
Want to see what other hedge funds are holding CRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CryoLife Inc. (NYSE:CRY).
Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.